

10/500517

DT15 PCT/PTO 29 JUN 2004

#3

"Express Mail" mailing label number	EL559725564US
Date of Deposit	6-29-04
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Printed Name	Signature
QUEEN THOMAS	Queen Thomas

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Peter Charles Astles et al.

For: Modulators of Acetylcholine Receptors

Docket No.: X-14688

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,



Mark A. Winter  
Agent for Applicants  
Registration No. 53,782  
Phone: 317-276-5362

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

6/23/04

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-14688	Serial No. <b>10/500517</b>
	Applicants Peter Charles Astles et al.	
	Filing Date	Group

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US 4,705,853	11-10-1987	Albert D. Cale, Jr.	
	AB	US 6,124,323	09-26-2000	Bigge et al.	
	AC	US			
	AD	US			
	AE	US			
	AF	US			
	AG	US			
	AH	US			
	AI	US			
	AJ	US			
	AK	US			
	AL	US			
	AM	US			
	AN	US			
	AO	US			
	AP	US			
	AQ	US			
	AR				

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-14688	Serial No. <b>10/500517</b>
	Applicants Peter Charles Astles et al.	
	Filing Date	Group

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	BA	EP-0 149 088-B1	07-24-1985	Degussa Aktengesellschaft		
	BB	EP-0 160 436-A2	11-06-1985	A. H. Robins Company, Inc.		
	BC	EP-0 304 888-B1	03-01-1989	Eisai Co., Ltd.		
	BD	EP-0 635 505-B1	01-25-1995	Merck Patent GmbH		
	BE	WO 97/19059	05-29-1997	Sibia Neurosciences, Inc.		
	BF	WO 99/32117	07-01-1999	Sibia Neurosciences, Inc.		
	BG	WO 01/51469-A1	07-19-2001	Merck Patent GMBH		
	BH	WO 01/81303-A1	11-01-2001	F. Hoffmann-La Roche AG		
	BI					
	BJ					
	BK					
	BL					
	BM					
	BN					
	BO					
	BP					
	BQ					
	BR					

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-14688	Serial No. <b>20/500517</b>
	Applicants Peter Charles Astles et al.	
	Filing Date	Group

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CA	STANISLAV RADL ET AL.: Synthesis and Analgesic Activity of some Deaza Derivatives of Anpirtoline, <i>Arch. Pharm. Pharm. Med. Chem.</i> , 1999, 13-18, 332	
	CB	WANG, HAO ET AL., Synthesis and biological activities of new 5-HT <sub>2A</sub> selective ligands N-substituted-piperidinyl-4-phenylthioether and sulfone derivatives, <i>Yaoxue Xuebao</i> , 2001, 274-277, Vol. 36, 4,	
	CC	RADL, STANISLAV ET AL., Molecular Modification of Anpirtoline, a Non-Opioid Centrally Acting Analgesic, <i>Collection of Czechoslovak Chem Comm</i> , 1999, 363-376, Vol. 64	
	CD		
	CE		
	CF		
	CG		
	CH		
	CI		
	CJ		
	CK		
	CL		
	CM		
	CN		
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.